SCHEMBL12876330

SCHEMBL12876330

Cc1cccc(-c2csc(CNN)n2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATP4A P20648 2/20 0.52
ATP4B P51164 2/20 0.52
PRMT6 Q96LA8 1/20 0.47
TSHR P16473 1/20 0.46
RECQL P46063 1/20 0.46
LTA4H P09960 1/20 0.45
LOXL2 Q9Y4K0 1/20 0.43
MEN1 O00255 5/20 0.43
KMT2A Q03164 5/20 0.43
RAB9A P51151 4/20 0.43
MAPT P10636 4/20 0.43
HDAC6 Q9UBN7 2/20 0.43
MAPK1 P28482 1/20 0.43
HTT P42858 1/20 0.43
TAAR1 Q96RJ0 1/20 0.42
C1S P09871 1/20 0.42
HDAC3 O15379 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
ALDH1A1 P00352 4/20 0.42
L3MBTL1 Q9Y468 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12876323 0.81 ATP4A (0.52) ATP4AATP4BPRMT6TSHRRECQL
SCHEMBL12876324 0.81 SCN9A (0.56) ATP4AATP4BPRMT6TSHRRECQL
SCHEMBL12876858 0.81 ATP4A (0.52) ATP4AATP4BPRMT6TSHRRECQL
SCHEMBL12890305 0.80 ALDH1A1 (0.50) LTA4HMEN1KMT2AALDH1A1CSNK2A2
Hydrochloric Acid SCHEMBL1198916 0.79 ALDH1A1 (0.49) LTA4HMEN1KMT2AALDH1A1CSNK2A2
SCHEMBL30118263 0.78 MEN1 (0.64) ATP4AATP4BTSHRRECQLMEN1
SCHEMBL28911568 0.78 MEN1 (0.64) ATP4AATP4BTSHRRECQLMEN1
SCHEMBL17887342 0.77 ATP4A (0.49) ATP4AATP4BPRMT6TSHRRECQL
SCHEMBL7120830 0.77 ALDH1A1 (0.65) ATP4AATP4BTSHRRECQLLTA4H
SCHEMBL8257849 0.75 RECQL (0.70) ATP4AATP4BPRMT6TSHRRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A ATP4A 2758/4885ATP4B 2711/4885PRMT6 424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.